Table 2.
Chromosomal gains and losses based on aCGH.
| Entity (number of cases) | Chromosomal gains (number of cases, if > 1) | Chromosomal losses (number of cases, if > 1) | % of samples with CIN |
|---|---|---|---|
| MSS CRC (13) | 2q32.2-33.1, 3p11.1-14.2, 3q11.2-13.11, 4q12-13.1, 5, 8, 8q (2), 7 (4), 12, 12p11.1-13.33, 12q12-24.11, 13 (5), 13q21.1-34, 14q24.1, 16, 16p, 16p11.2, 16q12.1-13, 17p11.2, 17q11.2-12, 17q21.1-21.2, 17q21.31-24.3, 19, 20 (3), 20p11.1-12, 20p11.21-11.23, 20p12.1-13, 20q (2) 20q11.21-11.23, X (2) | 1p11.1-22.3, 3p14.1-25.3, 3p14.2-26.3, 4 (4), 5q14.1, 5q14.2-23.3, 5q21.3-23.1, 8p (3), 8p12-23.3 (2), 8q11.21-11.22, 10q22.3-24.2, 10q23.31-25.3, 11, 11q22.1-23.3, 14 (2), 14q23.1-32.33, 15 (2), 15q11.2-13.3, 15q22.31-26.3, 16, 16p12.1-13.3, 16p12.3-13.3, 16q13-24.3, 16q21-24.3, 17p (4), 17p11.2-13.3, 17q12, 17q21.2-21.31, 18 (4), 18q12.1-23, 18q12.3-23, 19, 20p (2), 20p11.23-13, 20p12.1, 21, X | 100% |
| MSI-H CRC (18) | 1q (2), 6p, 7, 8 (4), 8q, 9 (2), 12, 13 (3), 17 (2), 17q, 19, 20, 22 | 3p, 3q, 4q (2), 5q12.2-14.3, 5q 14.3-22.2, 6q, 8p (2), 9p, 9q22.32-34.2, 10p15.3-13, 12, 12q, 15q11.2-13.1, 15q15.32-13.2, 15q25.1-26.3, 16q, 17, 18q, 20p, 22 | 78 % |
| MSI-L CRC (10) | 2 (2), 8q, 12 (2), 13 (2), 20, 20p, 20q | 1p, 4, 5q (2), 7, 8p (2), 10p, 10q, 14q, 17, 17p (2), 17q, 18 (2), 19p, 20p, 21 | 60% |
| HP (11) | - | - | 0 % |
| Small adenoma (LGD) (16) | - | - | 0 % |
| Large adenoma (LGD) (11) | 7 (2), 13, 20q (2) | 1p, 3p, 8q, 11q, 18q, 20p, 5p21.1-22.2 | 46 % |
| Adenoma (HGD (8) | 6p, 7, 8, 14, 16, 17, 17q, 20q (2), 22 | 1q, 2q, 2p, 4, 5q (2), 9p, 7, 18, 20p, 22 | 38 % |
| TSA (12) | 7, 13 | - | 8 % |
| SSA/P (26) | 15q12-13.2 | - | 4 % |
| SUM 125 | |||
Abbreviations: CRC colorectal cancer; MSS, microsatellite stable; MSI-H, high microsatellite instable; MSI-L, low microsatellite instable; HP, hyperplastic polyp; LGD, low grade dysplasia; HGD, high grade dysplasia; TSA, traditional serrated adenoma; SSA/P, sessile serrated adenoma/polyp.